MET and cancer: Collective evidence continues to buttress MET amplification as a shared genomic mechanism of off-target resistance and biomarker for subsequent rational combination strategy across oncogene-addicted lung cancers19,21,22, and underscores the clinical value of re-biopsy and comprehensive molecular profiling in therapy-resistant cancers.